Sarepta Therapeutics | Los Gastos De Explotación



Operating Expenses Cambio Fecha
Acadia Pharmaceuticals USD 106.1M 112.66M 2024-12
Agios Pharmaceuticals USD 135.77M 1.11B 2024-12
Alnylam Pharmaceuticals USD 698.32M 120.5M 2024-12
Amgen USD 6.78B 401M 2024-12
Biogen USD 2.01B 13.3M 2024-12
BioMarin Pharmaceutical USD 585.91M 45.94M 2024-12
Daiichi Sankyo JPY 435.08B 11.65B 2025-03
Eli Lilly USD 7.32B 1.06B 2025-03
Gilead Sciences USD 4.43B 687M 2025-03
Incyte USD 847.73M 29.46M 2025-03
Insmed USD 334.86M 28M 2024-12
Ionis Pharmaceuticals USD 278M 59.4M 2025-03
Moderna USD 1.16B 1.06B 2025-03
Neurocrine Biosciences USD 485.7M 47.4M 2024-12
Pfizer USD 10.05B 8.12B 2025-03
PTC Therapeutics USD 275.66M 24.36M 2024-12
Regeneron Pharmaceuticals USD 2.44B 362M 2025-03
Roche Holding CHF 11.43B 1.48B 2024-12
Sanofi EUR 8.32B 1.55B 2025-03
Sarepta Therapeutics USD 496.73M 51.76M 2024-12
Tectonic Therapeutic USD 13.99M 5.65M 2024-12
Ultragenyx Pharmaceutical USD 287.15M 15.67M 2024-12
Vertex Pharmaceuticals USD 1.89B 230.4M 2024-12



Sarepta Therapeutics Los Gastos De Explotación - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - May 2025.